Form 4: JNJ CEO Sells 100,000 Shares Under 10b5-1 Plan

Johnson & Johnson CEO and Chairman Joaquin Duato sold 100,000 shares of common stock for approximately $22.13 million on January 26, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Joaquin Duato, CEO and Chairman of the Board of Johnson & Johnson (JNJ), reported the sale of 100,000 shares of common stock.
• The transactions occurred on January 26, 2026, and were executed under a Rule 10b5-1(c) trading plan.
• One block of 51,218 shares was sold at a weighted average price of $220.986 per share.
• Another block of 48,782 shares was sold at a weighted average price of $221.484 per share.
• The total value of the shares sold is approximately $22,130,000.
• Following these transactions, Duato beneficially owns 387,441 shares of Johnson & Johnson common stock, including direct holdings, indirect holdings by spouse, and indirect holdings in a 401k plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sale is based on new, adverse material information. It is likely a planned liquidity event.

Positives

• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled liquidity event rather than a reaction to new material non-public information.

Negatives

• A significant sale of 100,000 shares by the CEO, even if pre-planned, represents a reduction in insider ownership.

Future Outlook

NA

Management Comments

• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

NA

Key Dates

Recommendation

The sale by CEO Joaquin Duato was executed under a pre-arranged 10b5-1 trading plan, which suggests it was a scheduled liquidity event rather than a reaction to new material non-public information. This type of transaction generally has a neutral impact on the investment thesis for Johnson & Johnson, warranting a 'hold' recommendation based solely on this filing. Investors should consider broader company fundamentals and market conditions for a comprehensive view.

Keywords

Johnson & Johnson, JNJ, Joaquin Duato, Insider Sale, Form 4, 10b5-1 Plan, Common Stock